41 results on '"Laterre, P.F."'
Search Results
2. Predictors of clinicians' underuse of daily sedation interruption and sedation scales
- Author
-
Sneyers, B., Henrard, S., Laterre, P.F., Perreault, M.M., Beguin, C., Wouters, D., Speybroeck, N., and Spinewine, A.
- Published
- 2017
- Full Text
- View/download PDF
3. Postoperative care of the pancreas transplant patient
- Author
-
Wittebole, X., primary, Laterre, P.F., additional, Castanares-Zapatero, D., additional, Mourad, M., additional, and Collienne, C., additional
- Published
- 2020
- Full Text
- View/download PDF
4. Contributors
- Author
-
Abrams, Peter, primary, Adler, Joel T., additional, Alejandro, Rodolfo, additional, Alibashe-Ahmed, Mohamed, additional, Alvarez, Ana, additional, Anazawa, Takayuki, additional, Andres, Axel, additional, Antonioli, Barbara, additional, Apete, Alan, additional, Axelrod, David A., additional, Badet, Lionel, additional, Baidal, David, additional, Barrera, Kaylene, additional, Benhamou, Pierre-Yves, additional, Berney, Thierry, additional, Bertoni, Alain Gerald, additional, Bertuzzi, Federico, additional, Boggi, Ugo, additional, Bonner, Caroline, additional, Bozorgzadeh, Adel, additional, Branchereau, Julien, additional, Bromberg, Jonathan, additional, Burke, George W., additional, Buron, Fanny, additional, Caiazzo, Robert, additional, Caldara, Rossana, additional, Camhi, Stephanie S., additional, Cantarovich, Diego, additional, Cardillo, Massimo, additional, Castanares-Zapatero, D., additional, Cattan, Pierre, additional, Chandran, Suresh Rama, additional, Chang, Erin, additional, Chen, Linda, additional, Chetboun, Mikael, additional, Choudhary, Pratik, additional, Ciancio, Gaetano, additional, Cicalese, Maria Pia, additional, Citro, Antonio, additional, Collienne, C., additional, Conte, Caterina, additional, Counter, Claire, additional, Dajani, Khaled Z., additional, Darden, Carly M., additional, De Cobelli, Francesco, additional, de Koning, Eelco J.P., additional, De Leon, Hector, additional, Delalleau, Nathalie, additional, DiChiacchio, Laura, additional, Doppenberg, Jason B., additional, Drachenberg, Cinthia B., additional, Dugnani, Erica, additional, Dunn, Ty B., additional, Engelse, Marten A., additional, Farag, Ahmed, additional, Farney, Alan, additional, Farrow, Anne Elizabeth, additional, Fathi, Ibrahim, additional, Figueiro, Jose, additional, Flatt, Anneliese, additional, Fousteri, Georgia, additional, Fridell, Jonathan A., additional, Friend, Peter J., additional, Gastaldi, Giacomo, additional, Gmyr, Valery, additional, Gonzalez, Javier, additional, Gopal, Jeevan Prakash, additional, Gorus, Frans K., additional, Goto, Masafumi, additional, Gotoh, Mitsukazu, additional, Greget, Michel, additional, Grenet, Dominique, additional, Grossi, Paolo Antonio, additional, Gruessner, Rainer W.G., additional, Gruessner, Angelika C., additional, Harriman, David I., additional, Hawthorne, Wayne J., additional, Hellman, Jarl, additional, Holbert, Brenda Lee, additional, Hubert, Thomas, additional, Iacopi, Sara, additional, Infante, Marco, additional, Jacob, Peter, additional, Johnson, Paul, additional, Kandaswamy, Raja, additional, Karam, Georges, additional, Kaufman, Dixon B., additional, Kendall Jr, W.F., additional, Kensinger, Clark D., additional, Kenyon, Norma S., additional, Kerr-Conte, Julie, additional, Kervella, Delphine, additional, Kessler, Laurence, additional, Kessler, Romain, additional, Keymeulen, Bart, additional, Korsgren, Olle, additional, Lablanche, Sandrine, additional, Lakhani, Muhaib, additional, Lalwani, Neeraj, additional, Laterre, P.F., additional, Lawrence, Michael C., additional, Lee, Frances Tangherlini, additional, Lehmann, Roger, additional, Linetsky, Elina, additional, Ludwig, Barbara, additional, Lundgren, Torbjörn, additional, Luo, Xunrong, additional, Madiraju, SriGita, additional, Maffi, Paola, additional, Magistretti, Paola, additional, Mapihan, Kristell Le, additional, Markmann, James F., additional, Martens, Geert, additional, Martins, Paulo N., additional, Mazzotta, Francesco Antonio, additional, Mekala, Kavya Chitra, additional, Melzi, Raffaella, additional, Mercalli, Alessia, additional, Monti, Paolo, additional, Morsi, Mahmoud, additional, Mosca, Irene, additional, Mourad, M., additional, Muthusamy, Anand S. Rathnasamy, additional, Nano, Rita, additional, Naziruddin, Bashoo, additional, Noel, Christian, additional, O’Callaghan, John, additional, Odorico, Jon S., additional, Olland, Anne, additional, Opara, E.C., additional, Orlando, Giuseppe, additional, Padilla, Nathalia, additional, Papadimitriou, John C., additional, Papalois, Vassilios E., additional, Papas, Klearchos K., additional, Pasquetti, Gianni, additional, Pattou, François, additional, Pellegrini, Silvia, additional, Pernin, Nadine, additional, Perrone, Vittorio Grazio, additional, Piemonti, Lorenzo, additional, Ploeg, Rutger, additional, Powelson, John A., additional, Pugliese, Alberto, additional, Rajan, Shanthini K., additional, Ramanathan, Karthik V., additional, Raverdy, Violeta, additional, Redfield, Robert R., additional, Renz, John, additional, Rickels, Michael R., additional, Rickert, Charles G., additional, Ricordi, Camillo, additional, Rogers, Jeffrey, additional, Scalea, Joseph R., additional, Schold, Jesse D., additional, Scholz, Hanne, additional, Secchi, Antonio, additional, Serrano, Oscar K., additional, Shapiro, A.M. James, additional, Sharma, Sidharth, additional, Sharples, Edward, additional, Shaw, James A.M., additional, Sinha, Sanjay, additional, Socci, Carlo, additional, Squifflet, Jean-Paul G., additional, Stock, Peter G., additional, Stratta, Robert J., additional, Sutherland, David E.R., additional, Tesauro, Manfredi, additional, Thaunat, Olivier, additional, Thévenet, Julien, additional, Troppmann, Christoph, additional, Vantyghem, Marie-Christine, additional, Vendrame, Francesco, additional, Venturini, Massimo, additional, Vianna, Rodrigo, additional, Vistoli, Fabio, additional, von Zur-Mühlen, Bengt, additional, Wittebole, X., additional, Wojtusciszyn, Anne, additional, Zarinsefat, Arya, additional, and Zimmerman, Asha, additional
- Published
- 2020
- Full Text
- View/download PDF
5. Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury.
- Author
-
Pickkers, P., Angus, D.C., Arend, J., Bellomo, R., Berg, Erik van den, Bernholz, J., Bestle, M., Broglio, K., Carlsen, J., Doig, C.J., Ferrer, R., Joannidis, M., Francois, B., Doi, K., Kellum, J.A., Laterre, P.F., Liu, Kathleen, Mehta, R.L., Murray, P.T., Ostermann, M., Pettilä, V., Richards, S., Young, P., Zarbock, A., Kjølbye, A.L., Pickkers, P., Angus, D.C., Arend, J., Bellomo, R., Berg, Erik van den, Bernholz, J., Bestle, M., Broglio, K., Carlsen, J., Doig, C.J., Ferrer, R., Joannidis, M., Francois, B., Doi, K., Kellum, J.A., Laterre, P.F., Liu, Kathleen, Mehta, R.L., Murray, P.T., Ostermann, M., Pettilä, V., Richards, S., Young, P., Zarbock, A., and Kjølbye, A.L.
- Abstract
Item does not contain fulltext, INTRODUCTION: Sepsis, the leading cause of acute kidney injury (AKI), is associated with a high morbidity and mortality. Alkaline phosphatase (ALP) is an endogenous detoxifying enzyme. A recombinant human ALP compound, ilofotase alfa, showed no safety or tolerability concerns in a phase 2 trial. Renal function improvement over 28 days was significantly greater in the ilofotase alfa group. Moreover, a significant relative reduction in 28-day all-cause mortality of >40% was observed. A follow-up trial has been designed to confirm these findings. METHODS AND ANALYSIS: This is a phase 3, global, multi-centre, randomised, double-blind, placebo-controlled, sequential design trial in which patients are randomly assigned to either placebo or 1.6 mg/kg ilofotase alfa. Randomisation is stratified by baseline modified Sequential Organ Failure Assessment (mSOFA) score and trial site. The primary objective is to confirm the survival benefit with ilofotase alfa by demonstrating a reduction in 28-day all-cause mortality in patients with sepsis-associated AKI requiring vasopressors. A maximum of 1400 patients will be enrolled at ∼120 sites in Europe, North America, Japan, Australia and New Zealand. Up to four interim analyses will take place. Based on predefined decision rules, the trial may be stopped early for futility or for effectiveness. In addition, patients with COVID-19 disease and patients with 'moderate to severe' chronic kidney disease are analysed as 2 separate cohorts of 100 patients each. An independent Data Monitoring Committee evaluates safety data at prespecified intervals throughout the trial. ETHICS AND DISSEMINATION: The trial is approved by relevant institutional review boards/independent ethics committees and is conducted in accordance with the ethical principles of the Declaration of Helsinki, guidelines of Good Clinical Practice, Code of Federal Regulations and all other applicable regulations. Results of this study will determine the potential of ilofotase
- Published
- 2023
6. Airway dysfunction and IgA immunity in COVID-unrelated and COVID-related ARDS
- Author
-
Gerard, L., primary, Lecocq, M., additional, Hoton, D., additional, Bouzin, C., additional, Laterre, P.F., additional, and Pilette, C., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Erratum to “TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus liberal calorie administration study” (1)
- Author
-
Singer, P., primary, De Waele, E., additional, Sanchez, C., additional, Ruiz Santana, S., additional, Montejo, J.C., additional, Laterre, P.F., additional, Soroksky, A., additional, Moscovici, E., additional, and Kagan, I., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: Post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial
- Author
-
Lier, D.P.T. van, Picod, Adrien, Marx, G., Laterre, P.F., Hartmann, O., Knothe, Claudia, Mebazaa, Alexandre, Pickkers, P., Lier, D.P.T. van, Picod, Adrien, Marx, G., Laterre, P.F., Hartmann, O., Knothe, Claudia, Mebazaa, Alexandre, and Pickkers, P.
- Abstract
Contains fulltext : 287443.pdf (Publisher’s version ) (Open Access)
- Published
- 2022
9. Adjunctive therapies for severe sepsis
- Author
-
Wittebole, X., Collienne, C., Castanares-Zapatero, D., and Laterre, P.F.
- Published
- 2008
- Full Text
- View/download PDF
10. Head-to-head comparison of cytokines storm-coagulopathy in septic shock and COVID-19
- Author
-
De Poortere, J., primary, Dechamps, M., additional, Laterre, P.F., additional, Octave, M., additional, Ginion, A., additional, Robaux, V., additional, Pirotton, L., additional, Bodart, J., additional, Gerard, L., additional, Gruson, D., additional, Van Dievoet, M.A., additional, Douxfils, J., additional, Derive, M., additional, Gatto, L., additional, Martin, M., additional, Bouzin, C., additional, Castanares-Zapatero, D., additional, Bertrand, L., additional, Horman, S., additional, and Beauloye, C., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
- Author
-
Laterre, P.F., Pickkers, P., Marx, G., Wittebole, X., Meziani, F., Dugernier, T., Huberlant, V., Schuerholz, T., François, B., Lascarrou, J.B., Beishuizen, A., Oueslati, H., Contou, D., Hoiting, O., Lacherade, J.C., Chousterman, B., Pottecher, J., Bauer, M, Godet, T., Karakas, M., Helms, J., Bergmann, A., Zimmermann, J., Richter, K., Hartmann, O., Pars, M., Mebazaa, A., Laterre, P.F., Pickkers, P., Marx, G., Wittebole, X., Meziani, F., Dugernier, T., Huberlant, V., Schuerholz, T., François, B., Lascarrou, J.B., Beishuizen, A., Oueslati, H., Contou, D., Hoiting, O., Lacherade, J.C., Chousterman, B., Pottecher, J., Bauer, M, Godet, T., Karakas, M., Helms, J., Bergmann, A., Zimmermann, J., Richter, K., Hartmann, O., Pars, M., and Mebazaa, A.
- Abstract
Item does not contain fulltext, PURPOSE: Investigate safety and tolerability of adrecizumab, a humanized monoclonal adrenomedullin antibody, in septic shock patients with high adrenomedullin. METHODS: Phase-2a, double-blind, randomized, placebo-controlled biomarker-guided trial with a single infusion of adrecizumab (2 or 4 mg/kg b.w.) compared to placebo. Patients with adrenomedullin above 70 pg/mL, < 12 h of vasopressor start for septic shock were eligible. Randomization was 1:1:2. Primary safety (90-day mortality, treatment emergent adverse events (TEAE)) and tolerability (drug interruption, hemodynamics) endpoints were recorded. Efficacy endpoints included the Sepsis Support Index (SSI, reflecting ventilator- and shock-free days alive), change in Sequential-related Organ Failure Assessment (SOFA) and 28-day mortality. RESULTS: 301 patients were enrolled (median time of 8.5 h after vasopressor start). Adrecizumab was well tolerated (one interruption, no hemodynamic alteration) with no differences in frequency and severity in TEAEs between treatment arms (TEAE of grade 3 or higher: 70.5% in the adrecizumab group and 71.1% in the placebo group) nor in 90-day mortality. Difference in change in SSI between adrecizumab and placebo was 0.72 (CI -1.93-0.49, p = 0.24). Among various secondary endpoints, delta SOFA score (defined as maximum versus minimum SOFA) was more pronounced in the adrecizumab combined group compared to placebo [difference at 0.76 (95% CI 0.18-1.35); p = 0.007]. 28-day mortality in the adrecizumab group was 23.9% and 27.7% in placebo with a hazard ratio of 0.84 (95% confidence interval 0.53-1.31, log-rank p = 0.44). CONCLUSIONS: Overall, we successfully completed a randomized trial evaluating selecting patients for enrolment who had a disease-related biomarker. There were no overt signals of harm with using two doses of the adrenomedullin antibody adrecizumab; however, further randomized controlled trials are required to confirm efficacy and safety of this agent in septic shock pat
- Published
- 2021
12. Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study
- Author
-
Blet, A., Deniau, Benjamin, Santos, Karine, Lier, D.P.T. van, Azibani, Feriel, Wittebole, X., Pickkers, P., Laterre, P.F., Mebazaa, Alexandre, Blet, A., Deniau, Benjamin, Santos, Karine, Lier, D.P.T. van, Azibani, Feriel, Wittebole, X., Pickkers, P., Laterre, P.F., and Mebazaa, Alexandre
- Abstract
Contains fulltext : 231612.pdf (publisher's version ) (Open Access)
- Published
- 2021
13. Chapter 17 - Postoperative care of the pancreas transplant patient
- Author
-
Wittebole, X., Laterre, P.F., Castanares-Zapatero, D., Mourad, M., and Collienne, C.
- Published
- 2020
- Full Text
- View/download PDF
14. Erratum to “TICACOS international: A multi-center, randomized, prospective controlled study comparing tight calorie control versus liberal calorie administration study” (1)
- Author
-
Singer, P., De Waele, E., Sanchez, C., Ruiz Santana, S., Montejo, J.C., Laterre, P.F., Soroksky, A., Moscovici, E., and Kagan, I.
- Published
- 2023
- Full Text
- View/download PDF
15. Oesophagectomy
- Author
-
Delvaux, B., primary, Kock, M. De, additional, and Laterre, P.F., additional
- Published
- 2008
- Full Text
- View/download PDF
16. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial
- Author
-
François, B., Wittebole, X., Ferrer, R., Mira, J.P., Dugernier, T., Gibot, S., Derive, M., Olivier, A., Cuvier, V., Witte, S., Pickkers, P., Vandenhende, F., Garaud, J.J., Sánchez, M., Salcedo-Magguilli, M., Laterre, P.F., François, B., Wittebole, X., Ferrer, R., Mira, J.P., Dugernier, T., Gibot, S., Derive, M., Olivier, A., Cuvier, V., Witte, S., Pickkers, P., Vandenhende, F., Garaud, J.J., Sánchez, M., Salcedo-Magguilli, M., and Laterre, P.F.
- Abstract
Contains fulltext : 225478.pdf (Publisher’s version ) (Closed access), PURPOSE: Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. This study evaluated the safety and pharmacokinetics of nangibotide and its effects on clinical and pharmacodynamic parameters in septic shock patients. METHODS: This was a multicenter randomized, double-blind, two-stage study. Patients received either continuous infusion of nangibotide (0.3, 1.0, or 3.0 mg/kg/h) or placebo. Treatment began < 24 h after shock onset and continued for up to 5 days. Safety primary outcomes were adverse events (AEs), whether serious or not, and death. Exploratory endpoints evaluated nangibotide effects on pharmacodynamics, organ function, and mortality, and were analyzed according to baseline sTREM-1 concentrations. RESULTS: Forty-nine patients were randomized. All treatment emergent AEs (TEAEs) were collected until Day 28. No significant differences were observed in TEAEs between treatment groups. No drug withdrawal linked to TEAE nor appearance of anti-drug antibodies were reported. Nangibotide pharmacokinetics appeared to be dose-proportional and clearance was dose-independent. Nangibotide did not significantly affect pharmacodynamic markers. Decrease in SOFA score LS mean change (± SE) from baseline to Day 5 in pooled nangibotide groups versus placebo was - 0.7 (± 0.85) in the randomized population and - 1.5 (± 1.12) in patients with high baseline plasma sTREM-1 concentrations (non-significant). This pattern was similar to organ support end points. CONCLUSION: No significant increases in TEAEs were detected in nangibotide-treated patients versus placebo. These results encourage further evaluation of nangibotide and further exploration of plasma sTREM-1 concentrations as a predictive efficacy biomarker.
- Published
- 2020
17. Défaillance multiviscérale précoce associée à la pancréatite aiguë : stratégie thérapeutique chirurgicale ou conservatrice ?
- Author
-
Dugernier, T, Laterre, P.F, and Reynaert, M.S
- Published
- 2003
- Full Text
- View/download PDF
18. Utilisation des modulateurs de la voie de la thrombine et de la protéine C dans les CIVD : résultats des essais cliniques
- Author
-
Laterre, P.F
- Published
- 2002
- Full Text
- View/download PDF
19. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)
- Author
-
Geven, C.B.C.A.G., Blet, A., Kox, M., Hartmann, O., Scigalla, P., Zimmermann, J., Marx, G., Laterre, P.F., Mebazaa, A., Pickkers, P., Geven, C.B.C.A.G., Blet, A., Kox, M., Hartmann, O., Scigalla, P., Zimmermann, J., Marx, G., Laterre, P.F., Mebazaa, A., and Pickkers, P.
- Abstract
Contains fulltext : 205501.pdf (publisher's version ) (Open Access), INTRODUCTION: Sepsis remains a major health problem with an increasing incidence, high morbidity and high mortality. Apart from treatment with antibiotics and organ support, no approved specific adjunct therapies currently exist. Adrenomedullin (ADM) is a vasoactive peptide. High plasma concentrations of ADM correlate with worse outcome in sepsis patients. Preclinical work with the non-neutralising ADM-binding antibody adrecizumab showed promising effects in animal models of septic shock, including improved vascular barrier function, reduced vasopressor demand and organ dysfunction and increased survival. Therapeutic use of adrecizumab may therefore improve outcome in critically ill patients with septic shock and high ADM plasma concentrations. Phase I studies in healthy volunteers did not reveal any safety concerns. In this biomarker-guided trial, the safety and efficacy of adrecizumab will be investigated in patients with septic shock. METHODS AND ANALYSIS: We describe a phase II, randomised, double-blind, placebo-controlled, biomarker-guided, proof-of-concept and dose-finding clinical trial in patients with early septic shock and high concentration of circulating ADM. A total of 300 patients will be enrolled at approximately 30 sites within the European Union. Patients are randomised to receive active treatment (2 and 4 mg/kg adrecizumab) or placebo, in a 1:1:2 ratio. Patient selection is guided by clinical parameters, and biomarker-guided by measurement of circulating biologically active ADM concentration at admission. Primary endpoint is safety and tolerability of adrecizumab over a 90-day period. A key secondary endpoint is the Sepsis Severity Index over a 14-day period. ETHICS AND DISSEMINATION: This study is approved by relevant institutional review boards/independent ethics committees and is conducted in accordance with the ethical principles of the Declaration of Helsinki, the European Medicines Agency guidelines of Good Clinical Practice and all other app
- Published
- 2019
20. Prise en charge des hépatites fulminantes d’origine toxique en réanimation
- Author
-
Wittebole, X and Laterre, P.F
- Published
- 2001
- Full Text
- View/download PDF
21. Corticothérapie au cours du choc septique et du syndrome de détresse respiratoire aiguë
- Author
-
Fourrier, F., Bricard, H., Cohen, Y., Daoud, P., Guidet, B., Huet, F., Laterre, P.F., Marquette, C.H., Schaller, M.D., Sollet, J.P., and Tamion, F.
- Published
- 2000
- Full Text
- View/download PDF
22. Progress in adult liver transplantation for acute liver failure
- Author
-
Lerut, J, Ciccarelli, O, Roggen, F, De Kock, M, Reding, R, Otte, J.B, Geubel, A.P, Reynaert, M.S, and Laterre, P.F
- Published
- 2000
- Full Text
- View/download PDF
23. Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial
- Author
-
Lewis, Roger J., Angus, D.C., Laterre, P.F., Kjolbye, Anne Louise, Meulen, Egbert van der, Blemings, Allan, Pickkers, P., Berry, Scott M., Lewis, Roger J., Angus, D.C., Laterre, P.F., Kjolbye, Anne Louise, Meulen, Egbert van der, Blemings, Allan, Pickkers, P., and Berry, Scott M.
- Abstract
Contains fulltext : 184039.pdf (publisher's version ) (Closed access)
- Published
- 2018
24. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study
- Author
-
Mebazaa, Alexandre, Geven, C.B.C.A.G., Hollinger, Alexa, Wittebole, X., Chousterman, Benjamin Glen, Blet, A., Pickkers, P., Legrand, M., Laterre, P.F., Mebazaa, Alexandre, Geven, C.B.C.A.G., Hollinger, Alexa, Wittebole, X., Chousterman, Benjamin Glen, Blet, A., Pickkers, P., Legrand, M., and Laterre, P.F.
- Abstract
Contains fulltext : 199454.pdf (publisher's version ) (Open Access)
- Published
- 2018
25. Erratum: Antimicrobials: A global alliance for optimizing their rational use in intra-abdominal infections (AGORA). [World J Emerg Surg. 11, (2016) (33)] DOI: 10.1186/s13017-016-0089-y
- Author
-
Sartelli, M. Weber, D.G. Ruppé, E. Bassetti, M. Wright, B.J. Ansaloni, L. Catena, F. Coccolini, F. Abu-Zidan, F.M. Coimbra, R. Moore, E.E. Moore, F.A. Maier, R.V. De Waele, J.J. Kirkpatrick, A.W. Griffiths, E.A. Eckmann, C. Brink, A.J. Mazuski, J.E. May, A.K. Sawyer, R.G. Mertz, D. Montravers, P. Kumar, A. Roberts, J.A. Vincent, J.L. Watkins, R.R. Lowman, W. Spellberg, B. Abbott, I.J. Adesunkanmi, A.K. Al-Dahir, S. Al-Hasan, M.N. Agresta, F. Althani, A.A. Ansari, S. Ansumana, R. Augustin, G. Bala, M. Balogh, Z.J. Baraket, O. Bhangu, A. Beltrán, M.A. Bernhard, M. Biffl, W.L. Boermeester, M.A. Brecher, S.M. Cherry-Bukowiec, J.R. Buyne, O.R. Cainzos, M.A. Cairns, K.A. Camacho-Ortiz, A. Chandy, S.J. Che Jusoh, A. Chichom-Mefire, A. Colijn, C. Corcione, F. Cui, Y. Curcio, D. Delibegovic, S. Demetrashvili, Z. De Simone, B. Dhingra, S. Diaz, J.J. Di Carlo, I. Dillip, A. Di Saverio, S. Doyle, M.P. Dorj, G. Dogjani, A. Dupont, H. Eachempati, S.R. Enani, M.A. Egiev, V.N. Elmangory, M.M. Ferrada, P. Fitchett, J.R. Fraga, G.P. Guessennd, N. Giamarellou, H. Ghnnam, W. Gkiokas, G. Goldberg, S.R. Gomes, C.A. Gomi, H. Guzmán-Blanco, M. Haque, M. Hansen, S. Hecker, A. Heizmann, W.R. Herzog, T. Hodonou, A.M. Hong, S.K. Kafka-Ritsch, R. Kaplan, L.J. Kapoor, G. Karamarkovic, A. Kees, M.G. Kenig, J. Kiguba, R. Kim, P.K. Kluger, Y. Khokha, V. Koike, K. Kok, K.Y. Kong, V. Knox, M.C. Inaba, K. Isik, A. Iskandar, K. Ivatury, R.R. Labbate, M. Labricciosa, F.M. Laterre, P.F. Latifi, R. Lee, J.G. Lee, Y.R. Leone, M. Leppaniemi, A. Li, Y. Liang, S.Y. Loho, T. Maegele, M. Malama, S. Marei, H.E. Martin-Loeches, I. Marwah, S. Massele, A. McFarlane, M. Melo, R.B. Negoi, I. Nicolau, D.P. Nord, C.E. Ofori-Asenso, R. Omari, A.H. Ordonez, C.A. Ouadii, M. Pereira Júnior, G.A. Piazza, D. Pupelis, G. Rawson, T.M. Rems, M. Rizoli, S. Rocha, C. Sakakushev, B. Sanchez-Garcia, M. Sato, N. Segovia Lohse, H.A. Sganga, G. Siribumrungwong, B. Shelat, V.G. Soreide, K. Soto, R. Talving, P. Tilsed, J.V. Timsit, J.F. Trueba, G. Trung, N.T. Ulrych, J. van Goor, H. Vereczkei, A. Vohra, R.S. Wani, I. Uhl, W. Xiao, Y. Yuan, K.C. Zachariah, S.K. Zahar, J.R. Zakrison, T.L. Corcione, A. Melotti, R.M. Viscoli, C. Viale, P.
- Subjects
lipids (amino acids, peptides, and proteins) - Abstract
The original article [1] contains an error whereby a co-author, Boris Sakakushev has their family name spelt incorrectly as 'Sakakhushev'. The authors would therefore like it known that the correct spelling of the family name is 'Sakakushev'. © The Author(s).
- Published
- 2017
26. Non–Heart-Beating Donor, 10-Year Experience in a Belgian Transplant Center
- Author
-
Malaise, J., Van Deynse, D., Dumont, V., Lecomte, C., Mourad, M., Dufrane, D., Squifflet, J.P., Van Ophem, D., Verschuren, F., Meert, P., Thys, F., El Gariani, A., Wittebole, X., Laterre, P.F., and Hantson, P.
- Published
- 2007
- Full Text
- View/download PDF
27. Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference
- Author
-
Bellomo, R., Ronco, C., Mehta, R.L., Asfar, P., Boisrame-Helms, J., Darmon, M., Diehl, J.L., Duranteau, J., Hoste, E.A.J., Olivier, J.B., Legrand, M., Lerolle, N., Malbrain, M., Martensson, J., Oudemans-van Straaten, H.M., Parienti, J.J., Payen, D., Perinel, S., Peters, E., Pickkers, P., Rondeau, E., Schetz, M., Vinsonneau, C., Wendon, J., Zhang, L., Laterre, P.F., Bellomo, R., Ronco, C., Mehta, R.L., Asfar, P., Boisrame-Helms, J., Darmon, M., Diehl, J.L., Duranteau, J., Hoste, E.A.J., Olivier, J.B., Legrand, M., Lerolle, N., Malbrain, M., Martensson, J., Oudemans-van Straaten, H.M., Parienti, J.J., Payen, D., Perinel, S., Peters, E., Pickkers, P., Rondeau, E., Schetz, M., Vinsonneau, C., Wendon, J., Zhang, L., and Laterre, P.F.
- Abstract
Contains fulltext : 174812.pdf (publisher's version ) (Open Access), The French Intensive Care Society organized its yearly Paris International Conference in intensive care on June 18-19, 2015. The main purpose of this meeting is to gather the best experts in the field in order to provide the highest quality update on a chosen topic. In 2015, the selected theme was: "Acute Renal Failure in the ICU: from injury to recovery." The conference program covered multiple aspects of renal failure, including epidemiology, diagnosis, treatment and kidney support system, prognosis and recovery together with acute renal failure in specific settings. The present report provides a summary of every presentation including the key message and references and is structured in eight sections: (a) diagnosis and evaluation, (b) old and new diagnosis tools
- Published
- 2017
28. Breakthrough in cardiac arrest: reports from the 4th Paris International Conference
- Author
-
Kudenchuk, P.J., Sandroni, C., Drinhaus, H.R., Böttiger, B.W., Cariou, A., Sunde, K., Dworschak, M., Taccone, F.S., Deye, N., Friberg, H., Laureys, S., Ledoux, D., Oddo, M., Legriel, S., Hantson, P., Diehl, J.L., and Laterre, P.F.
- Abstract
Jean-Luc Diehl The French Intensive Care Society organized on 5th and 6th June 2014 its 4th "Paris International Conference in Intensive Care", whose principle is to bring together the best international experts on a hot topic in critical care medicine. The 2014 theme was "Breakthrough in cardiac arrest", with many high-quality updates on epidemiology, public health data, pre-hospital and in-ICU cares. The present review includes short summaries of the major presentations, classified into six main chapters: Epidemiology of CA Pre-hospital management Post-resuscitation management: targeted temperature management Post-resuscitation management: optimizing organ perfusion and metabolic parameters Neurological assessment of brain damages Public healthcare.
- Published
- 2015
29. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.
- Author
-
Laterre, P.F., Wittebole, X., Velde, S. van der, Muller, A.E., Mouton †, J.W., Carryn, S., Tulkens, P.M., Dugernier, T., Laterre, P.F., Wittebole, X., Velde, S. van der, Muller, A.E., Mouton †, J.W., Carryn, S., Tulkens, P.M., and Dugernier, T.
- Abstract
Item does not contain fulltext
- Published
- 2015
30. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.
- Author
-
Pickkers, P., Heemskerk, S., Schouten, J.A., Laterre, P.F., Vincent, J.L., Beishuizen, A., Jorens, P.G., Spapen, H., Bulitta, M., Peters, W.H.M., Hoeven, J.G. van der, Pickkers, P., Heemskerk, S., Schouten, J.A., Laterre, P.F., Vincent, J.L., Beishuizen, A., Jorens, P.G., Spapen, H., Bulitta, M., Peters, W.H.M., and Hoeven, J.G. van der
- Abstract
Contains fulltext : 108970.pdf (publisher's version ) (Open Access), INTRODUCTION: To evaluate whether alkaline phosphatase (AP) treatment improves renal function in sepsis-induced acute kidney injury (AKI), a prospective, double-blind, randomized, placebo-controlled study in critically ill patients with severe sepsis or septic shock with evidence of AKI was performed. METHODS: Thirty-six adult patients with severe sepsis or septic shock according to Systemic Inflammatory Response Syndrome criteria and renal injury defined according to the AKI Network criteria were included. Dialysis intervention was standardized according to Acute Dialysis Quality Initiative consensus. Intravenous infusion of alkaline phosphatase (bolus injection of 67.5 U/kg body weight followed by continuous infusion of 132.5 U/kg/24 h for 48 hours, or placebo) starting within 48 hours of AKI onset and followed up to 28 days post-treatment. The primary outcome variable was progress in renal function variables (endogenous creatinine clearance, requirement and duration of renal replacement therapy, RRT) after 28 days. The secondary outcome variables included changes in circulating inflammatory mediators, urinary excretion of biomarkers of tubular injury, and safety. RESULTS: There was a significant (P = 0.02) difference in favor of AP treatment relative to controls for the primary outcome variable. Individual renal parameters showed that endogenous creatinine clearance (baseline to Day 28) was significantly higher in the treated group relative to placebo (from 50 +/- 27 to 108 +/- 73 mL/minute (mean +/- SEM) for the AP group; and from 40 +/- 37 to 65 +/- 30 mL/minute for placebo; P = 0.01). Reductions in RRT requirement and duration did not reach significance. The results in renal parameters were supported by significantly more pronounced reductions in the systemic markers C-reactive protein, Interleukin-6, LPS-binding protein and in the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18 in AP-treated patients relative to placebo. The Drug Safety Monit
- Published
- 2012
31. 912 CLINICAL MANAGEMENT OF ACUTE LIVER FAILURE 2010: RESULTS OF A PAN-EUROPEAN SURVEY
- Author
-
Bernal, W., primary, Han, Y., additional, Laterre, P.F., additional, Lee, A., additional, Mas, A., additional, Murphy, N., additional, Stolze-larsen, F., additional, Wauters, J., additional, Wendon, J., additional, and Samuel, D., additional
- Published
- 2011
- Full Text
- View/download PDF
32. Current Surgical Management of Acute Pancreatitis
- Author
-
Dugernier, Th., primary, Dewaele, J., additional, and Laterre, P.F., additional
- Published
- 2006
- Full Text
- View/download PDF
33. Exclusion endovasculaire des anevrysmes visceraux par stents couverts
- Author
-
Goffette, P.P., primary, Laterre, P.F., additional, Gigot, J.F., additional, Wittebole, X., additional, and Tombal, B., additional
- Published
- 2005
- Full Text
- View/download PDF
34. Perforation sigmoïdienne traumatique : intérêt du bilan tomodensitométrique
- Author
-
Geukens, D., primary, Danse, E., additional, Verschuren, F., additional, Kartheuser, A., additional, Mauel, E., additional, and Laterre, P.F., additional
- Published
- 2005
- Full Text
- View/download PDF
35. La ventilation non invasive dans l'asthme aigu grave, une nouvelle attitude thérapeutique?
- Author
-
Thys, F, primary, Roeseler, J, additional, Marion, E, additional, El Gariani, A, additional, Danse, E, additional, Meert, P, additional, Laterre, P.F., additional, Matte, P, additional, Jacquet, L, additional, and Reynaert, M.S., additional
- Published
- 1998
- Full Text
- View/download PDF
36. A84 EFFECTS OF IV CLONIDINE AS AN ADJUNCT TO ANESTHESIA DURING ORTHOTOPIC LIVER TRANSPLANTATIONS
- Author
-
Dubois, P., primary, De Kock, M., additional, and Laterre, P.F., additional
- Published
- 1997
- Full Text
- View/download PDF
37. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents: myopathy-myosin-critical illness
- Author
-
Deconinck, N., primary, Van Parijs, V., additional, Laterre, P.F., additional, Reynaert, M., additional, Vormezeele, R., additional, and Van den Bergh, P., additional
- Published
- 1997
- Full Text
- View/download PDF
38. Transjugular intrahepatic portosystemic shunt after adult liver transplantation: experience in eight patients
- Author
-
Lerut, J.P., Goffette, P., Molle, G., Roggen, F.M., Puttemans, T., Brenard, R., Morelli, M.C., Wallemacq, P., Van Beers, B., and Laterre, P.F.
- Published
- 1999
- Full Text
- View/download PDF
39. Liver Transplantation and HBsAg-positive Postnecrotic Cirrhosis: Adequate Immunoprophylaxis and delta Virus Co-infection as the Significant Determinants of Long-term Prognosis
- Author
-
Lerut, J.P., Donataccio, M., Ciccarelli, O., Roggen, F., Jamart, J., Laterre, P.F., Cornu, C., Mazza, D., Hanique, G., Rahier, J., Geubel, A.P., and Otte, J.B.
- Subjects
Hepatitis B -- Prognosis ,Liver -- Transplantation ,Health ,Prognosis - Abstract
Liver Transplantation Lerut, J.P.; Donataccio, M.; Ciccarelli, O.; Roggen, F.; Jamart, J.; Laterre, P.F.; Cornu, C.; Mazza, D.; Hanique, G.; Rahier, J.; Geubel, A.P.; Otte, J.B. 'Liver Transplantation and HBsAg-positive [...]
- Published
- 1999
40. Impact of oversedation prevention in ventilated critically ill patients: a randomized trial-the AWARE study
- Author
-
Thierry Jacques, Bernard De Jonghe, Qin Lu, Jean-Luc Baudel, Vincent Das, Jean Reignier, Guillaume Carteaux, Stephan Ehrmann, Gaëtan Plantefève, Bernard Lambermont, Emmanuelle Gourdin, Jean-Philippe Rigaud, Nadia Aissaoui, Hervé Clavier, Hervé Hyvernat, Michael Piagnerelli, Romain Hernu, Lucas Liaudet, David Grimaldi, Karim Chergui, Annabelle Stoclin, Jean-François Hicter, Jean-Claude Lacherade, François Vincent, Philippe Michel, Grégoire Muller, Aurélie Cravoisy-Popovic, Laurent Guérin, Olfa Hamzaoui, F. Brouard, Emmanuel Vivier, Sébastien Ena, Nicolas Devos, Jugurtha Aliane, Antoine Kimmoun, Laurence Donetti, Pierre-François Laterre, Frédérique Ganster, Antoine Gros, Laetitia Bodet-Contentin, Alexandre Duguet, Jean-Paul Mira, Djillali Annane, Cédric Cleophax, Jean-Damien Ricard, Siu-Ming Au, Alexis Soumer, Stéphane Merat, Walter Picard, Alexandre Cambonie, Charles-Edouard Luyt, Nicolas Deye, Charlotte Quentin, Julie Léger, Frédéric Jacobs, Patrick Girardie, Sandie Dauriac, Isabelle Camilatto, Jean-Luc Desmaretz, Xavier Monnet, Philippe Obbee, René Robert, Daniel da Silva, Christophe Girault, Corinne Audoin, Alain Mercat, D.A. Reuter, Renaud Chouquer, Mohebbi Amoli Abolfazl, Fabienne Plouvier, Elie Azoulay, Thierry Boulain, Maleka Schenck, Bruno Giraudeau, Gilles Troché, Jérôme Aboab, Stéphane Legriel, SRLF Trial Group, de Jonghe, B., Aboab, J., Aissaoui, N., Annane, D., Audoin, C., Baudel, J.L., Brouard, F., Cambonie, A., Camilatto, I., Chergui, K., Das, V., da Silva, D., Devos, N., Deye, N., Ehrmann, S., Ganster, F., Giraudeau, B., Grimaldi, D., Gourdin, E., Gros, A., Hamzaoui, O., Jacobs, F., Kimmoun, A., Lacherade, J.C., Lambermont, B., Laterre, P.F., Leger, J., Legriel, S., Liaudet, L., Luyt, C.E., Michel, P., Mira, J.P., Monnet, X., Muller, G., Piagnerelli, M., Plantefeve, G., Reignier, J., Ricard, J.D., Vincent, F., Aliane, J., Plouvier, F., Mercat, A., Abolfazl, M.A., Cleophax, C., Carteaux, G., Troche, G., Guerin, L., Girardie, P., Vivier, E., Hernu, R., Obbee, P., Donetti, L., Jacques, T., Cravoisy-Popovic, A., Boulain, T., Lu, Q., Reuter, D., Azoulay, E., Clavier, H., Picard, W., Robert, R., Chouquer, R., Girault, C., Merat, S., Quentin, C., Hicter, J.F., Schenck, M., Dauriac, S., Desmaretz, J.L., Hyvernat, H., Soumer, A., Stoclin, A., Rigaud, J.P., Duguet, A., Bodet-Contentin, L., Au, S.M., Ena, S., UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, and UCL - (SLuc) Service de soins intensifs
- Subjects
medicine.medical_specialty ,Sedation ,medicine.medical_treatment ,Weaning ,Critical Care and Intensive Care Medicine ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Mechanical ventilation ,Randomized controlled trial ,law ,medicine ,030212 general & internal medicine ,Mortality ,Intensive care medicine ,Intensive care units ,business.industry ,Critically ill ,Research ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,030208 emergency & critical care medicine ,lcsh:RC86-88.9 ,medicine.symptom ,business - Abstract
Background Although oversedation has been associated with increased morbidity in ventilated critically ill patients, it is unclear whether prevention of oversedation improves mortality. We aimed to assess 90-day mortality in patients receiving a bundle of interventions to prevent oversedation as compared to usual care. Methods In this randomized multicentre trial, all adult patients requiring mechanical ventilation for more than 48 h were included. Two groups were compared: patients managed according to usual sedation practices (control), and patients receiving sedation according to an algorithm which provided a gradual multilevel response to pain, agitation, and ventilator dyssynchrony with no specific target to alter consciousness and no use of sedation scale and promoted the use of alternatives to continuous infusion of midazolam or propofol (intervention). Results Inclusions were stopped before reaching the planned enrolment. Between 2012 and 2014, 584 patients were included in the intervention group and 590 in the control group. Baseline characteristics were well balanced between groups. Although the use of midazolam and propofol was significantly lower in the intervention group, 90-day mortality was not significantly lower (39.4 vs. 44.2% in the control group, p = 0.09). There were no significant differences in 1-year mortality between the two groups. The time to first spontaneous breathing trial and time to successful extubation were significantly shorter in the intervention group than in the control group. These last results should be interpreted with precaution regarding the several limitations of the trial including the early termination. Conclusions This underpowered study of severely ill patients was unable to show that a strategy to prevent oversedation could significantly reduce mortality. Trial registration NCT01617265
- Published
- 2018
41. Fluid challenges in intensive care: the FENICE study: a global inception cohort study
- Author
-
Cecconi, M1, Hofer, C, Teboul, Jl, Pettila, V, Wilkman, E, Molnar, Z, Della Rocca, G, Aldecoa, C, Artigas, A, Jog, S, Sander, M, Spies, C, Lefrant, Jy, De Backer, D, Silva, E, Zhang, X, Ospina-tascón, G, Arias, J, Gornik, I, Benes, J, Petersen, A, Zsolt, M, Sprung, C, Koch, M, Guttormsen, Ab, Tavares, M, Pettilä, V, Mikaszewska-sokolewicz, M, Bakker, J, Parke, R, Kirov, M, Wernerman, J, Esen, F, Cecconi, M, Cannesson, M, Njimi, H, François, G, Cueto, G, Hockley, S, Ambekar, H, Laterre, Pf, Dujardin, Mf, Damas, P, Deschamps, P, Glorieux, D, Hoste, E, Miribung, M, Devriendt, J, Haentjens, L, Biston, P, Dugernier, T, Bulpa, P, Dive, A, Debaveye, Y, Franck, S, Conde, K, Morsch, R, Ramos, M, Dias, F, Mataloun, S, Mendes, C, Silva, F, Grion, C, Knibel, M, Yang, C, Xiangyu, Z, Cai, G, Ortiz, G, Ospina-tascon, G, Yepes, D, Londono Arcila Hf, Molina, F, Pereira, F, Sanchez-galvez, Hf, Benitez, F, Arias Ortiz, J, Gonzalez Rojas, M, Cavric, G, Lukic, E, Zykova, I, Freml, P, Satinsky, I, Suk, P, Novak, I, Balik, M, Szturz, P, Kratochvil, M, Bestle, M, Strange, Dg, Perner, A, Rasmussen, Bs, Hauge, J, Meldgaard, M, Toome, V, Kuitunen, A, Varila, S, Hovilehto, S, Pulkkinen, A, Kiviniemi, O, Tallgren, M, Laitio, R, Mongardon, N, Dhonneur, G, Malledant, Y, Lepouse, C, Darmon, M, Mira, Jp, Chiche, Jd, Joannes-boyau, O, Preau, S, Larche, J, Mottard, N, Bengler, C, Argaud, L, Hamzaoui, O, Desebbe, O, Burtin, P, Reignier, J, Durand, M, Guitard, Pg, Asfar, P, Guillot, M, Boulain, T, Mekontso Dessap, A, Ducrocq, N, Lakhal, K, Gregoire, C, Schmauss, M, Zacharowski, K, Meybohm, P, Treskatsch, S, Bloos, F, Van Huelst, S, Baumann, H, Kersten, A, Goldmann, A, Gkiokas, G, Dimoula, A, Kofinas, G, Anthopoulos, G, Pankotai, B, Kopitko, C, Gartner, B, Schaffer, E, Fulesdi, B, Sarkany, A, Samavedam, S, Shah, B, Dixit, S, Toraskar, K, Nandakumar, S, Goila, Ak, Nayyar, A, Patel, M, Mitra, D, Jagiasi, B, Jakkinaboina, S, Goswami, J, Ghosh, S, Hashemian, M, Mahmoodpoor, A, Breen, D, Benbenishty, J, Kuniavsky, M, Kolpak, O, Castiglione, G, Monti, G, Molin, A, Martucci, G, Panarello, G, Raineri, Sm, Pota, V, Acquarolo, A, Ploner, F, Lapichino, G, Lombardo, A, Roasio, A, Cardelino, S, Pignataro, A, Oggioni, R, Mangani, V, Parrini, V, Spadaro, S, Volta, Ca, Alampi, D, Torrente, S, Monastra, L, Marini, F, Mazzini, P, Albanese, D, Riccardi, S, Ruberto, F, Belluomo, Ac, Silvestri, R, Citerio, G, Brienza, N, Brazzi, L, Protti, A, Bottino, N, David, A, Manzoni, D, Foti, G, Numis, F, Morimatsu, H, Shimizu, K, Munster, L, Rai, V, Buttigieg, M, Pickkers, P, Mijzen, L, Kesecioglu, J, Van Duijn, D, Ormskerk, P, Beck, O, Goodson, J, King, B, Koelle, J, Kantor, S, Gomez, O, Ramos, I, Jedynak, M, Sulkowski, W, Adamik, B, Chruscikowski, M, Wadelek, J, Korzybski, J, Misiewska-kaczur, A, Piasecka-twarog, M, Fijaikowska, A, Maciejewski, D, Smiechowicz, K, Milkowska, E, Czerwinska, A, Lukaszewska, A, Wieczorek, A, Czuczwar, M, Czerwiec, A, Tamowicz, B, Branco, V, Estilita, J, Basilio, C, Diogo, C, Toma, R, Bubenek-turconi, Si, Filipescu, D, Popescu, M, Titova, J, Belskiy, V, Smetkin, A, Grigoryev, E, Pugachev, S, Gasenkampf, A, Abouelala, A, Almekhlafi, G, Rupnik, E, Garcia-delgado, H, Saez Fernandez, A, Celaya Lopez, M, Ramasco, F, Planas, K, Zavala, E, De Nadal, M, Picos, Sa, Fernandez, S, Munoz, A, Herrera Para, L, Maseda, E, Rovira, A, Monge Garcia Mi, Ferrer, R, Sole Violan, J, Garcia Nogales, X, Torrents, E, Ripolles Melchor, J, Tomás Marsilla Ji, Araujo Aguilar, P, Aguilar, G, Menor, Em, Martinez, Mc, Leal Micharet Am, Ferri Riera, C, Mosquera, D, Astola, I, Freita-ramos, S, Garcia Olivares, P, Jimenez Bartolome Mb, Fernandez Gonzalez, I, Sanchez-izquierdo, Ja, Arribas, P, Gimenez-esparzavich, C, Anglada, M, Martin, S, Weerakoon, Rk, Bendjelid, K, Fumeaux, T, Maggiorini, M, Demirkiran, O, Adanir, T, Ergin Ozcan, P, Kelebek Girgin, N, Elahi, N, Kashef, S, Alsabbah, A, Lowe, A, Wise, M, Vizcaychipi, Mp, Baht, S, Webb, S, Friis, J, Boulanger, C, Gratrix, A, Harvey, D, Ferguson, A, Espie, L, Toth-tarsoly, P, Lewis, K, Shelley, B, Thuerey, J, Przemyslaw, D, Ranganathan, M, Hormis, A, Spivey, M, Henning, J, Saveker, R, Csabi, P, Bland, M, Barrera Groba, C, Al-subaie, N, Thomson, R, Hamilton, M, Iannuccelli, F, Roberts, C, Sherwood, N, Kasipandian, V, Silversides, J, Jonas, A, Szakmany, T, Vickers, E, Richards, J, Tham, L, Williams, D, Heenen, S, Hobrok, M, Walden, A, Raj, A, Bauer, P, Kashyap, R, Tolnai, P, Kjelle, Bj, Andersen, Fh, Palo, Je, Namendys-silva, S. A., Hôpital Bicêtre, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Cecconi M., Hofer C., Teboul J.-L., Pettila V., Wilkman E., Molnar Z., Della Rocca G., Aldecoa C., Artigas A., Jog S., Sander M., Spies C., Lefrant J.-Y., De Backer D., Silva E., Zhang X., Ospina-Tascon G., Arias J., Gornik I., Benes J., Petersen A., Zsolt M., Sprung C., Koch M., Guttormsen A.B., Tavares M., Mikaszewska-Sokolewicz M., Bakker J., Parke R., Kirov M., Wernerman J., Esen F., Cannesson M., Njimi H., Francois G., Cueto G., Hockley S., Ambekar H., Laterre P.F., Dujardin M.F., Damas P., Deschamps P., Glorieux D., Hoste E., Miribung M., Devriendt J., Haentjens L., Biston P., Dugernier T., Bulpa P., Dive A., Debaveye Y., Franck S., Conde K., Morsch R., Ramos M., Dias F., Mataloun S., Mendes C., Silva F., Grion C., Knibel M., Yang C., Xiangyu Z., Cai G., Ortiz G., Yepes D., Londono Arcila H.F., Molina F., Pereira F., Sanchez-Galvez H.F., Benitez F., Arias Ortiz J., Gonzalez Rojas M., Cavric G., Lukic E., Zykova I., Freml P., Satinsky I., Suk P., Novak I., Balik M., Szturz P., Kratochvil M., Bestle M., Strange D.G., Perner A., Rasmussen B.S., Hauge J., Meldgaard M., Toome V., Kuitunen A., Varila S., Hovilehto S., Pulkkinen A., Kiviniemi O., Tallgren M., Laitio R., Mongardon N., Dhonneur G., Malledant Y., Lepouse C., Darmon M., Mira J.P., Chiche J.D., Joannes-Boyau O., Preau S., Larche J., Mottard N., Bengler C., Argaud L., Hamzaoui O., Desebbe O., Burtin P., Reignier J., Durand M., Guitard P.G., Asfar P., Guillot M., Boulain T., Mekontso Dessap A., Ducrocq N., Lakhal K., Gregoire C., Schmauss M., Zacharowski K., Meybohm P., Treskatsch S., Bloos F., van Huelst S., Baumann H., Kersten A., Goldmann A., Gkiokas G., Dimoula A., Kofinas G., Anthopoulos G., Pankotai B., Kopitko C., Gartner B., Schaffer E., Fulesdi B., Sarkany A., Samavedam S., Shah B., Dixit S., Toraskar K., Nandakumar S., Goila A.K., Nayyar A., Patel M., Mitra D., Jagiasi B., Jakkinaboina S., Goswami J., Ghosh S., Hashemian M., Mahmoodpoor A., Breen D., Benbenishty J., Kuniavsky M., Kolpak O., Castiglione G., Monti G., Molin A., Martucci G., Panarello G., Raineri S.M., Pota V., Acquarolo A., Ploner F., Lapichino G., Lombardo A., Roasio A., Cardelino S., Pignataro A., Oggioni R., Mangani V., Parrini V., Spadaro S., Volta C.A., Alampi D., Torrente S., Monastra L., Marini F., Mazzini P., Albanese D., Riccardi S., Ruberto F., Belluomo A.C., Silvestri R., Citerio G., Brienza N., Brazzi L., Protti A., Bottino N., David A., Manzoni D., Foti G., Numis F., Morimatsu H., Shimizu K., Munster L., Rai V., Buttigieg M., Pickkers P., Mijzen L., Kesecioglu J., Van Duijn D., Ormskerk P., Beck O., Goodson J., King B., Koelle J., Kantor S., Gomez O., Ramos I., Jedynak M., Sulkowski W., Adamik B., Chruscikowski M., Wadelek J., Korzybski J., Misiewska-Kaczur A., Piasecka-Twarog M., Fijaikowska A., Maciejewski D., Smiechowicz K., Milkowska E., Czerwinska A., Lukaszewska A., Wieczorek A., Czuczwar M., Czerwiec A., Tamowicz B., Branco V., Estilita J., Basilio C., Diogo C., Toma R., Bubenek-Turconi S.I., Filipescu D., Popescu M., Titova J., Belskiy V., Smetkin A., Grigoryev E., Pugachev S., Gasenkampf A., Abouelala A., Almekhlafi G., Rupnik E., Garcia-Delgado H., Saez Fernandez A., Celaya Lopez M., Ramasco F., Planas K., Zavala E., De Nadal M., Picos S.A., Fernandez S., Munoz A., Herrera Para L., Maseda E., Rovira A., Monge Garcia M.I., Ferrer R., Sole Violan J., Garcia Nogales X., Torrents E., Ripolles Melchor J., Tomas Marsilla J.I., Araujo Aguilar P., Aguilar G., Menor E.M., Martinez M.C., Leal Micharet A.M., Ferri Riera C., Mosquera D., Astola I., Freita-Ramos S., Garcia Olivares P., Jimenez Bartolome M.B., Fernandez Gonzalez I., Sanchez-Izquierdo J.A., Arribas P., Gimenez-Esparzavich C., Anglada M., Martin S., Weerakoon R.K., Bendjelid K., Fumeaux T., Maggiorini M., Demirkiran O., Adanir T., Ergin Ozcan P., Kelebek Girgin N., Elahi N., Kashef S., Alsabbah A., Lowe A., Wise M., Vizcaychipi M.P., Baht S., Webb S., Friis J., Boulanger C., Gratrix A., Harvey D., Ferguson A., Espie L., Toth-Tarsoly P., Lewis K., Shelley B., Thuerey J., Przemyslaw D., Ranganathan M., Hormis A., Spivey M., Henning J., Saveker R., Csabi P., Bland M., Barrera Groba C., Al-Subaie N., Thomson R., Hamilton M., Iannuccelli F., Roberts C., Sherwood N., Kasipandian V., Silversides J., Jonas A., Szakmany T., Vickers E., Richards J., Tham L., Williams D., Heenen S., Hobrok M., Walden A., Raj A., Bauer P., Kashyap R., Tolnai P., Kjelle B.J., Andersen F.H., Palo J.E., Namendys-Silva S.A., Cecconi, M, Hofer, C, Teboul, J, Pettila, V, Wilkman, E, Molnar, Z, Della Rocca, G, Aldecoa, C, Artigas, A, Jog, S, Sander, M, Spies, C, Lefrant, J, De Backer, D, Silva, E, Zhang, X, Ospina-Tascon, G, Arias, J, Gornik, I, Benes, J, Petersen, A, Zsolt, M, Sprung, C, Koch, M, Guttormsen, A, Tavares, M, Mikaszewska-Sokolewicz, M, Bakker, J, Parke, R, Kirov, M, Wernerman, J, Esen, F, Cannesson, M, Njimi, H, Francois, G, Cueto, G, Hockley, S, Ambekar, H, Laterre, P, Dujardin, M, Damas, P, Deschamps, P, Glorieux, D, Hoste, E, Miribung, M, Devriendt, J, Haentjens, L, Biston, P, Dugernier, T, Bulpa, P, Dive, A, Debaveye, Y, Franck, S, Conde, K, Morsch, R, Ramos, M, Dias, F, Mataloun, S, Mendes, C, Silva, F, Grion, C, Knibel, M, Yang, C, Xiangyu, Z, Cai, G, Ortiz, G, Yepes, D, Londono Arcila, H, Molina, F, Pereira, F, Sanchez-Galvez, H, Benitez, F, Arias Ortiz, J, Gonzalez Rojas, M, Cavric, G, Lukic, E, Zykova, I, Freml, P, Satinsky, I, Suk, P, Novak, I, Balik, M, Szturz, P, Kratochvil, M, Bestle, M, Strange, D, Perner, A, Rasmussen, B, Hauge, J, Meldgaard, M, Toome, V, Kuitunen, A, Varila, S, Hovilehto, S, Pulkkinen, A, Kiviniemi, O, Tallgren, M, Laitio, R, Mongardon, N, Dhonneur, G, Malledant, Y, Lepouse, C, Darmon, M, Mira, J, Chiche, J, Joannes-Boyau, O, Preau, S, Larche, J, Mottard, N, Bengler, C, Argaud, L, Hamzaoui, O, Desebbe, O, Burtin, P, Reignier, J, Durand, M, Guitard, P, Asfar, P, Guillot, M, Boulain, T, Mekontso Dessap, A, Ducrocq, N, Lakhal, K, Gregoire, C, Schmauss, M, Zacharowski, K, Meybohm, P, Treskatsch, S, Bloos, F, van Huelst, S, Baumann, H, Kersten, A, Goldmann, A, Gkiokas, G, Dimoula, A, Kofinas, G, Anthopoulos, G, Pankotai, B, Kopitko, C, Gartner, B, Schaffer, E, Fulesdi, B, Sarkany, A, Samavedam, S, Shah, B, Dixit, S, Toraskar, K, Nandakumar, S, Goila, A, Nayyar, A, Patel, M, Mitra, D, Jagiasi, B, Jakkinaboina, S, Goswami, J, Ghosh, S, Hashemian, M, Mahmoodpoor, A, Breen, D, Benbenishty, J, Kuniavsky, M, Kolpak, O, Castiglione, G, Monti, G, Molin, A, Martucci, G, Panarello, G, Raineri, S, Pota, V, Acquarolo, A, Ploner, F, Lapichino, G, Lombardo, A, Roasio, A, Cardelino, S, Pignataro, A, Oggioni, R, Mangani, V, Parrini, V, Spadaro, S, Volta, C, Alampi, D, Torrente, S, Monastra, L, Marini, F, Mazzini, P, Albanese, D, Riccardi, S, Ruberto, F, Belluomo, A, Silvestri, R, Citerio, G, Brienza, N, Brazzi, L, Protti, A, Bottino, N, David, A, Manzoni, D, Foti, G, Numis, F, Morimatsu, H, Shimizu, K, Munster, L, Rai, V, Buttigieg, M, Pickkers, P, Mijzen, L, Kesecioglu, J, Van Duijn, D, Ormskerk, P, Beck, O, Goodson, J, King, B, Koelle, J, Kantor, S, Gomez, O, Ramos, I, Jedynak, M, Sulkowski, W, Adamik, B, Chruscikowski, M, Wadelek, J, Korzybski, J, Misiewska-Kaczur, A, Piasecka-Twarog, M, Fijaikowska, A, Maciejewski, D, Smiechowicz, K, Milkowska, E, Czerwinska, A, Lukaszewska, A, Wieczorek, A, Czuczwar, M, Czerwiec, A, Tamowicz, B, Branco, V, Estilita, J, Basilio, C, Diogo, C, Toma, R, Bubenek-Turconi, S, Filipescu, D, Popescu, M, Titova, J, Belskiy, V, Smetkin, A, Grigoryev, E, Pugachev, S, Gasenkampf, A, Abouelala, A, Almekhlafi, G, Rupnik, E, Garcia-Delgado, H, Saez Fernandez, A, Celaya Lopez, M, Ramasco, F, Planas, K, Zavala, E, De Nadal, M, Picos, S, Fernandez, S, Munoz, A, Herrera Para, L, Maseda, E, Rovira, A, Monge Garcia, M, Ferrer, R, Sole Violan, J, Garcia Nogales, X, Torrents, E, Ripolles Melchor, J, Tomas Marsilla, J, Araujo Aguilar, P, Aguilar, G, Menor, E, Martinez, M, Leal Micharet, A, Ferri Riera, C, Mosquera, D, Astola, I, Freita-Ramos, S, Garcia Olivares, P, Jimenez Bartolome, M, Fernandez Gonzalez, I, Sanchez-Izquierdo, J, Arribas, P, Gimenez-Esparzavich, C, Anglada, M, Martin, S, Weerakoon, R, Bendjelid, K, Fumeaux, T, Maggiorini, M, Demirkiran, O, Adanir, T, Ergin Ozcan, P, Kelebek Girgin, N, Elahi, N, Kashef, S, Alsabbah, A, Lowe, A, Wise, M, Vizcaychipi, M, Baht, S, Webb, S, Friis, J, Boulanger, C, Gratrix, A, Harvey, D, Ferguson, A, Espie, L, Toth-Tarsoly, P, Lewis, K, Shelley, B, Thuerey, J, Przemyslaw, D, Ranganathan, M, Hormis, A, Spivey, M, Henning, J, Saveker, R, Csabi, P, Bland, M, Barrera Groba, C, Al-Subaie, N, Thomson, R, Hamilton, M, Iannuccelli, F, Roberts, C, Sherwood, N, Kasipandian, V, Silversides, J, Jonas, A, Szakmany, T, Vickers, E, Richards, J, Tham, L, Williams, D, Heenen, S, Hobrok, M, Walden, A, Raj, A, Bauer, P, Kashyap, R, Tolnai, P, Kjelle, B, Andersen, F, Palo, J, Namendys-Silva, S, De Backer, Daniel, Cecconi, M., Hofer, C., Teboul, J. -L., Pettila, V., Wilkman, E., Molnar, Z., Della Rocca, G., Aldecoa, C., Artigas, A., Jog, S., Sander, M., Spies, C., Lefrant, J. -Y., De Backer, D., Silva, E., Zhang, X., Ospina-Tascon, G., Arias, J., Gornik, I., Benes, J., Petersen, A., Zsolt, M., Sprung, C., Koch, M., Guttormsen, A. B., Tavares, M., Mikaszewska-Sokolewicz, M., Bakker, J., Parke, R., Kirov, M., Wernerman, J., Esen, F., Cannesson, M., Njimi, H., Francois, G., Cueto, G., Hockley, S., Ambekar, H., Laterre, P. F., Dujardin, M. F., Damas, P., Deschamps, P., Glorieux, D., Hoste, E., Miribung, M., Devriendt, J., Haentjens, L., Biston, P., Dugernier, T., Bulpa, P., Dive, A., Debaveye, Y., Franck, S., Conde, K., Morsch, R., Ramos, M., Dias, F., Mataloun, S., Mendes, C., Silva, F., Grion, C., Knibel, M., Yang, C., Xiangyu, Z., Cai, G., Ortiz, G., Yepes, D., Londono Arcila, H. F., Molina, F., Pereira, F., Sanchez-Galvez, H. F., Benitez, F., Arias Ortiz, J., Gonzalez Rojas, M., Cavric, G., Lukic, E., Zykova, I., Freml, P., Satinsky, I., Suk, P., Novak, I., Balik, M., Szturz, P., Kratochvil, M., Bestle, M., Strange, D. G., Perner, A., Rasmussen, B. S., Hauge, J., Meldgaard, M., Toome, V., Kuitunen, A., Varila, S., Hovilehto, S., Pulkkinen, A., Kiviniemi, O., Tallgren, M., Laitio, R., Mongardon, N., Dhonneur, G., Malledant, Y., Lepouse, C., Darmon, M., Mira, J. P., Chiche, J. D., Joannes-Boyau, O., Preau, S., Larche, J., Mottard, N., Bengler, C., Argaud, L., Hamzaoui, O., Desebbe, O., Burtin, P., Reignier, J., Durand, M., Guitard, P. G., Asfar, P., Guillot, M., Boulain, T., Mekontso Dessap, A., Ducrocq, N., Lakhal, K., Gregoire, C., Schmauss, M., Zacharowski, K., Meybohm, P., Treskatsch, S., Bloos, F., van Huelst, S., Baumann, H., Kersten, A., Goldmann, A., Gkiokas, G., Dimoula, A., Kofinas, G., Anthopoulos, G., Pankotai, B., Kopitko, C., Gartner, B., Schaffer, E., Fulesdi, B., Sarkany, A., Samavedam, S., Shah, B., Dixit, S., Toraskar, K., Nandakumar, S., Goila, A. K., Nayyar, A., Patel, M., Mitra, D., Jagiasi, B., Jakkinaboina, S., Goswami, J., Ghosh, S., Hashemian, M., Mahmoodpoor, A., Breen, D., Benbenishty, J., Kuniavsky, M., Kolpak, O., Castiglione, G., Monti, G., Molin, A., Martucci, G., Panarello, G., Raineri, S. M., Pota, V., Acquarolo, A., Ploner, F., Lapichino, G., Lombardo, A., Roasio, A., Cardelino, S., Pignataro, A., Oggioni, R., Mangani, V., Parrini, V., Spadaro, S., Volta, C. A., Alampi, D., Torrente, S., Monastra, L., Marini, F., Mazzini, P., Albanese, D., Riccardi, S., Ruberto, F., Belluomo, A. C., Silvestri, R., Citerio, G., Brienza, N., Brazzi, L., Protti, A., Bottino, N., David, A., Manzoni, D., Foti, G., Numis, F., Morimatsu, H., Shimizu, K., Munster, L., Rai, V., Buttigieg, M., Pickkers, P., Mijzen, L., Kesecioglu, J., Van Duijn, D., Ormskerk, P., Beck, O., Goodson, J., King, B., Koelle, J., Kantor, S., Gomez, O., Ramos, I., Jedynak, M., Sulkowski, W., Adamik, B., Chruscikowski, M., Wadelek, J., Korzybski, J., Misiewska-Kaczur, A., Piasecka-Twarog, M., Fijaikowska, A., Maciejewski, D., Smiechowicz, K., Milkowska, E., Czerwinska, A., Lukaszewska, A., Wieczorek, A., Czuczwar, M., Czerwiec, A., Tamowicz, B., Branco, V., Estilita, J., Basilio, C., Diogo, C., Toma, R., Bubenek-Turconi, S. I., Filipescu, D., Popescu, M., Titova, J., Belskiy, V., Smetkin, A., Grigoryev, E., Pugachev, S., Gasenkampf, A., Abouelala, A., Almekhlafi, G., Rupnik, E., Garcia-Delgado, H., Saez Fernandez, A., Celaya Lopez, M., Ramasco, F., Planas, K., Zavala, E., De Nadal, M., Picos, S. A., Fernandez, S., Munoz, A., Herrera Para, L., Maseda, E., Rovira, A., Monge Garcia, M. I., Ferrer, R., Sole Violan, J., Garcia Nogales, X., Torrents, E., Ripolles Melchor, J., Tomas Marsilla, J. I., Araujo Aguilar, P., Aguilar, G., Menor, E. M., Martinez, M. C., Leal Micharet, A. M., Ferri Riera, C., Mosquera, D., Astola, I., Freita-Ramos, S., Garcia Olivares, P., Jimenez Bartolome, M. B., Fernandez Gonzalez, I., Sanchez-Izquierdo, J. A., Arribas, P., Gimenez-Esparzavich, C., Anglada, M., Martin, S., Weerakoon, R. K., Bendjelid, K., Fumeaux, T., Maggiorini, M., Demirkiran, O., Adanir, T., Ergin Ozcan, P., Kelebek Girgin, N., Elahi, N., Kashef, S., Alsabbah, A., Lowe, A., Wise, M., Vizcaychipi, M. P., Baht, S., Webb, S., Friis, J., Boulanger, C., Gratrix, A., Harvey, D., Ferguson, A., Espie, L., Toth-Tarsoly, P., Lewis, K., Shelley, B., Thuerey, J., Przemyslaw, D., Ranganathan, M., Hormis, A., Spivey, M., Henning, J., Saveker, R., Csabi, P., Bland, M., Barrera Groba, C., Al-Subaie, N., Thomson, R., Hamilton, M., Iannuccelli, F., Roberts, C., Sherwood, N., Kasipandian, V., Silversides, J., Jonas, A., Szakmany, T., Vickers, E., Richards, J., Tham, L., Williams, D., Heenen, S., Hobrok, M., Walden, A., Raj, A., Bauer, P., Kashyap, R., Tolnai, P., Kjelle, B. J., Andersen, F. H., Palo, J. E., Namendys-Silva, S. A., Clinicum, Department of Diagnostics and Therapeutics, and Anestesiologian yksikkö
- Subjects
Male ,Soins intensifs réanimation ,medicine.medical_treatment ,Cohort Studies ,Female ,Humans ,Middle Aged ,Practice Patterns, Physicians' ,Critical Care ,Fluid Therapy ,Critical Care and Intensive Care Medicine ,Practice Patterns ,ESICM Trial Group ,RESPONSIVENESS ,Seven-Day Profile Publication ,Medicine and Health Sciences ,FENICE Investigators ,CIRCULATORY SHOCK ,intensive care ,ddc:617 ,RENAL REPLACEMENT THERAPY ,3. Good health ,OF-THE-LITERATURE ,SHOCK ,lipids (amino acids, peptides, and proteins) ,Erratum ,intensive care, fluid therapy ,fluids ,Life Sciences & Biomedicine ,CRITICALLY-ILL PATIENTS ,Human ,Cohort study ,medicine.medical_specialty ,HYDROXYETHYL STARCH 130/0.4 ,MEDLINE ,1117 Public Health and Health Services ,NO ,fluid therapy ,Critical Care Medicine ,CIRCULATORY ,General & Internal Medicine ,Intensive care ,Anesthesiology ,PATIENTS ,medicine ,cohort study ,Renal replacement therapy ,Intensive care medicine ,Physicians' ,Science & Technology ,CRITICALLY-ILL ,business.industry ,Septic shock ,SEPTIC SHOCK ,1103 Clinical Sciences ,3126 Surgery, anesthesiology, intensive care, radiology ,medicine.disease ,Emergency & Critical Care Medicine ,ARTERIAL-PRESSURE ,SEVERE SEPSIS ,Clinical trial ,Observational study ,Cohort Studie ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,TASK-FORCE - Abstract
Background: Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC. Methods: This was an observational study conducted in ICUs around the world. Each participating unit entered a maximum of 20 patients with one FC. Results: 2213 patients were enrolled and analyzed in the study. The median [interquartile range] amount of fluid given during an FC was 500 ml (500–1000). The median time was 24 min (40–60 min), and the median rate of FC was 1000 [500–1333] ml/h. The main indication for FC was hypotension in 1211 (59 %, CI 57–61 %). In 43 % (CI 41–45 %) of the cases no hemodynamic variable was used. Static markers of preload were used in 785 of 2213 cases (36 %, CI 34–37 %). Dynamic indices of preload responsiveness were used in 483 of 2213 cases (22 %, CI 20–24 %). No safety variable for the FC was used in 72 % (CI 70–74 %) of the cases. There was no statistically significant difference in the proportion of patients who received further fluids after the FC between those with a positive, with an uncertain or with a negatively judged response. Conclusions: The current practice and evaluation of FC in critically ill patients are highly variable. Prediction of fluid responsiveness is not used routinely, safety limits are rarely used, and information from previous failed FCs is not always taken into account., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.